Uniqure N.V. (QURE) Stock Price & Analysis
Uniqure N.V. (QURE) fell 1.17% to USD 38.97 as of July 25, 2026 at 03:44 UTC, according to Nexqual real-time market data.
QURE last closed at USD 39.43; the session ranged USD 37.34–39.44 on volume of 1,318,734 shares. Market capitalization is $2.68B, with a 52-week range of USD 8.73–71.5 (NMS). Source: Nexqual, July 25, 2026 at 03:44 UTC.
Key Statistics (as of July 25, 2026 at 03:44 UTC)
| Price | USD 38.97 |
|---|---|
| Change | ▼ 1.17% (down) |
| Previous Close | USD 39.43 |
| Open | USD 39.31 |
| Day Range | USD 37.34 – 39.44 |
| 52-Week Range | USD 8.73 – 71.5 |
| Volume | 1,318,734 shares |
| Market Cap | $2.68B |
| Exchange | NMS |
Technical Analysis (QURE)
Nexqual's technical model rates QURE "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 03:44 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 53.19 (neutral) |
| vs SMA50 | Above (USD 35.37) |
| MACD | 0.78 (positive) |
Analyst Ratings (QURE)
Wall Street analysts rate QURE "Strong Buy" based on 11 analysts, with a mean price target of USD 64.51 (range USD 35.81–92.33), per Nexqual as of July 25, 2026 at 03:44 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 64.51 |
| High Target | USD 92.33 |
| Low Target | USD 35.81 |
| Buy / Hold / Sell | 11 / 2 / 0 |
Earnings (QURE)
| Next Earnings Date | 2026-07-29 |
|---|---|
| EPS Estimate | USD -0.71 |
| Revenue Estimate | $4.71M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.73 vs est -0.75 ▲ beat |
| 2025-12-31 | USD -0.47 vs est -0.78 ▲ beat |
| 2025-09-30 | USD -1.19 vs est -0.75 ▼ miss |
| 2025-06-30 | USD -0.6 vs est -0.76 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:44 UTC.
Financials & Fundamentals (QURE)
| Total Revenue | $18.09M |
|---|---|
| Revenue Growth (YoY) | +127.30% |
| Gross Margin | +0.00% |
| Operating Margin | -1321.11% |
| Profit Margin | +0.00% |
| ROE | -228.24% |
| Debt / Equity | 365.37 |
| Current Ratio | 10.4 |
| Total Cash | $586.55M |
| Total Debt | $545.66M |
| Free Cash Flow | $-103.70M |
Source: Nexqual, July 25, 2026 at 03:44 UTC.
Financial Health Score (QURE)
Nexqual rates Uniqure N.V.'s overall financial health "Critical" across five dimensions, as of July 25, 2026 at 03:44 UTC.
| Growth | Critical — Revenue -48% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Weak — $587M cash vs $546M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$104M, burning cash |
| Efficiency | Critical — ROE -228%, ROA -17.0% |
Ownership (QURE)
| Insider Ownership | +1.29% |
|---|---|
| Institutional Ownership | +86.46% |
| Shares Outstanding | 68.75M |
| Float | 56.53M |
| Short % of Float | +16.95% |
Source: Nexqual, July 25, 2026 at 03:44 UTC.
Leadership (QURE)
Uniqure N.V. is led by Matthew Craig Kapusta (age 53), CEO & Executive Director, per Nexqual as of July 25, 2026 at 03:44 UTC.
| CEO & Executive Director | Matthew Craig Kapusta (age 53) |
|---|---|
| CFO, Principal Financial Officer & GM of Amsterdam Site | Christian Klemt (age 52) |
| Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | Hugo Katus |
| Senior Director of Investor Relations | Chiara Elizabeth Russo |
| Business Development Director | Tamara Tugal |
Major Backers & Investors (QURE)
Notable institutional backers of Uniqure N.V. include Avoro Capital Advisors LLC, Aberdeen Group plc, JPMorgan, according to Nexqual as of July 25, 2026 at 03:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Avoro Capital Advisors LLC | 9.45% |
| Aberdeen Group plc | 8.41% |
| JPMorgan | 5.39% |
| abrdn Healthcare Investors | 4.85% |
| Two Sigma Investments, LP | 4.24% |
| RTW Investments LP | 4.1% |
| Orbimed Advisors LLC. | 3.39% |
| FMR, LLC | 2.77% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| State Street | 7.37% |
| BlackRock | 3.4% |
Source: Nexqual, July 25, 2026 at 03:44 UTC.
From Uniqure N.V.'s Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
- The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding.
- Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease.
- The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RGNX | REGENXBIO Inc. | USD 9.73 | ▼ 4.61% |
| RARE | Ultragenyx Pharmaceutical Inc. | USD 26.9 | ▼ 2.69% |
| VYGR | Voyager Therapeutics, Inc. | USD 3.1 | ▲ 0% |
| PTCT | PTC Therapeutics, Inc. | USD 76.82 | ▼ 2.02% |
| MGNX | MacroGenics, Inc. | USD 3.7 | ▼ 13.95% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:44 UTC. This page is informational and not investment advice.